2
Clinical Trials associated with LY-900021A Study to Investigate the Tolerability of Subcutaneous Injections of LY3074828 Compared to Placebo
The purpose of this study is to evaluate different concentrations and formulations of LY3074828 compared to placebo ("dummy drug").
The study will consist of 2 parts: Part A and Part B. Screening is required within 28 days prior to the start of each study part. For each participant in Part A and Part B, the total duration of the clinical trial will be approximately 16 weeks, including screening.
An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given together with LY9999QS compared to LY3074828 alone. The tolerability of the different formulations will also be evaluated and information about any side effects experienced will be collected.
Screening is required within 28 days prior to the start of the study. For each participant the total duration of the clinical trial will be approximately 13 weeks, not including screening.
100 Clinical Results associated with LY-900021
100 Translational Medicine associated with LY-900021
100 Patents (Medical) associated with LY-900021
100 Deals associated with LY-900021